Eli Lilly and Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eli Lilly and Company
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.
First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
Biologics with their brand name dropped from the label could become the alternative to an ‘authorized biosimilar,’ which is not allowed under the law.
- Other Names / Subsidiaries
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
- Disarm Therapeutics, Inc.